BackgroundGlanzmann thrombasthenia (GT) is a rare congenital platelet function disorder associated with severe bleeding diathesis. Thrombotic manifestations remain condition. We report here the first case of recurrent venous thromboembolism (VTE) successfully treated apixaban in patient GT. Our patient’s morbid obesity was an additional challenge.Key Clinical QuestionThe Key Question to determi...

BACKGROUND Glanzmann Thrombasthenia (GT) is a genetic platelet dysfunction and a life threatening disease. Ankaferd Blood Stopper (ABS) is a topical hemostatic agent of herbal origin which has been recently made available for clinical use. Its hemostatic effect is independent from blood clotting factors and occurs as a result of the aggregation of focal red blood cells by an encapsulated protei...

A 19-year-old woman with a qualitative variant of Glanzmann Thrombasthenia (GT) was referred to our department for her first pregnancy. The diagnosis of GT was revealed by epistaxis and gingival bleeding. Her history of bleeding was limited to dental procedures and haemorrhagic rupture of an ovarian cyst under platelet transfusion. Her husband had normal platelet function tests and no consangui...

We studied the defect responsible for Glanzmann thrombasthenia in a patient whose platelets expressed < 5% of the normal amount of GPIIb-IIIa. Genetic and biochemical evidence indicated that the patient's GPIIIa genes were normal. However, DNA analysis revealed the patient homozygous for a G818-->A substitution in her GPIIb genes, resulting in a Gly273-->Asp substitution adjacent to the first G...

A sensitive immunoblot technique for platelet glycoprotein lIla (GPllla) was used to analyze the platelets of patients living in Israel who meet the diagnostic criteria for type I Glanzmann thrombasthenia. When reacted with solubilized normal platelets, a rabbit antiserum to GPIIIa identified a major band at molecular weight (mol wt) 90.000 and three additional minor bands at Mr 1 1 0.000. 81 ....

A sensitive immunoblot technique for platelet glycoprotein lIla (GPllla) was used to analyze the platelets of patients living in Israel who meet the diagnostic criteria for type I Glanzmann thrombasthenia. When reacted with solubilized normal platelets, a rabbit antiserum to GPIIIa identified a major band at molecular weight (mol wt) 90.000 and three additional minor bands at Mr 1 1 0.000. 81 ....

Starting 90 years ago with a clinical description by Glanzmann of a bleeding disorder associated with a defect in platelet function, technologic advances helped investigators identify the defect as a mutation(s) in the integrin family receptor, IIb 3, which has the capacity to bind fibrinogen (and other ligands) and support platelet-platelet interactions (aggregation). The receptor’s activation...

The mechanism of action of recombinant factor VIIa (rFVIIa), i.e. increased thrombin generation on the membrane of activated platelets, as well as the results from in vitro and ex vivo models of thrombocytopenia or inherited thrombocytopathia may support some potential of rFVIIa in thrombocytopenia/thrombocytopathia. rFVIIa was reported as effective to stop or to decrease bleeding in few patien...